PMID- 34179028
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210629
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine 
      Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.
PG  - 570921
LID - 10.3389/fmed.2021.570921 [doi]
LID - 570921
AB  - EGFR tyrosine kinase inhibitors (TKIs) are the front-line treatment in EGFR 
      mutation positive advanced non-small cell lung cancer (aNSCLC) patients. 
      Generally, they are well-tolerated but skin toxicity is common (45-100% of 
      patients) and may adversely affect quality of life. Pathogenesis of cutaneous 
      side effects is usually linked to EGFR expression in normal cells of the 
      epidermis and not immune-related. Subacute cutaneous lupus erythematosus (SCLE) 
      is an autoimmune disease and about 40% of SCLE cases are drug related, but no 
      reports are available involving osimertinib. Our report depicts a drug 
      induced-SCLE (DI-SCLE) caused by erlotinib and worsened by osimertinib. The 
      adverse event is characterized by the absence of systemic symptoms. Diagnosis has 
      been performed by skin biopsy and the conditions improved with systemic steroids 
      administration and EGFR-TKIs discontinuation. The report underlines the 
      importance of a complete dermatologic diagnosis of skin lesions induced by EGFR 
      inhibitors, according to symptom severity and timing of improving with standard 
      clinical management. The diagnosis of immune-related skin toxicity in this 
      context affects the treatment and the outcome of skin toxicity and must be taken 
      into account when planning subsequent treatments, potentially including immune 
      checkpoint inhibitors (ICIs).
CI  - Copyright (c) 2021 Ferro, Filoni, Pavan, Pasello, Guarneri, Conte, Alaibac and 
      Bonanno.
FAU - Ferro, Alessandra
AU  - Ferro A
AD  - Department of Surgery, Oncology and Gastroenterology, Universita degli Studi di 
      Padova, Padova, Italy.
AD  - Medical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a 
      Carattere Scientifico (IRCCS), Padova, Italy.
FAU - Filoni, Angela
AU  - Filoni A
AD  - Melanoma and Sarcoma Surgical Oncology Unit - Veneto Institute of Oncology, 
      IOV-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy.
FAU - Pavan, Alberto
AU  - Pavan A
AD  - Medical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a 
      Carattere Scientifico (IRCCS), Padova, Italy.
FAU - Pasello, Giulia
AU  - Pasello G
AD  - Medical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a 
      Carattere Scientifico (IRCCS), Padova, Italy.
FAU - Guarneri, Valentina
AU  - Guarneri V
AD  - Department of Surgery, Oncology and Gastroenterology, Universita degli Studi di 
      Padova, Padova, Italy.
AD  - Medical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a 
      Carattere Scientifico (IRCCS), Padova, Italy.
FAU - Conte, PierFranco
AU  - Conte P
AD  - Department of Surgery, Oncology and Gastroenterology, Universita degli Studi di 
      Padova, Padova, Italy.
AD  - Medical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a 
      Carattere Scientifico (IRCCS), Padova, Italy.
FAU - Alaibac, Mauro
AU  - Alaibac M
AD  - Unit of Dermatology, University of Padua, Padua, Italy.
FAU - Bonanno, Laura
AU  - Bonanno L
AD  - Medical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a 
      Carattere Scientifico (IRCCS), Padova, Italy.
LA  - eng
PT  - Case Reports
DEP - 20210604
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8220808
OTO - NOTNLM
OT  - cutaneous drug reactions
OT  - immune- related adverse events
OT  - immunotherapy
OT  - osimertinib
OT  - targeted therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/06/29 06:00
MHDA- 2021/06/29 06:01
PMCR- 2021/06/04
CRDT- 2021/06/28 06:05
PHST- 2021/04/07 00:00 [received]
PHST- 2021/05/13 00:00 [accepted]
PHST- 2021/06/28 06:05 [entrez]
PHST- 2021/06/29 06:00 [pubmed]
PHST- 2021/06/29 06:01 [medline]
PHST- 2021/06/04 00:00 [pmc-release]
AID - 10.3389/fmed.2021.570921 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Jun 4;8:570921. doi: 10.3389/fmed.2021.570921. 
      eCollection 2021.